The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Sharp John P since 2013.
This trader's CIK number is 1342894.
At the time of last reporting, Sharp John P was the Chief Financial Officer of Phasebio Pharmaceuticals Inc. (stock ticker symbol PHAS).
Also see all insider trading activities at Phasebio Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2014 | LGND | 0 | $0 | 86,953 | $6,500,345 | 86,953 | $1,572,805 |
| 2013 | LGND | 0 | $0 | 15,323 | $754,024 | 8,824 | $87,887 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | PHAS | 0 | $0 | 0 | $0 | 7,500 | $12,600 |
| 2020 | PHAS | 0 | $0 | 0 | $0 | 5,000 | $8,450 |
| 2019 | PHAS | 0 | $0 | 0 | $0 | 30,000 | $48,825 |
| 2018 | PHAS | 5,000 | $19,200 | 0 | $0 | 0 | $0 |
1. Ligand Pharmaceuticals Inc (LGND)
2. Phasebio Pharmaceuticals Inc (PHAS)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2014-02-12 | LGND | Sale | 86,953 | 74.76 | 6,500,345 |
| 2014-02-12 | LGND | Option Ex | 86,953 | 18.09 | 1,572,805 |
| 2013-12-12 | LGND | Option Ex | 700 | 9.96 | 6,972 |
| 2013-12-12 | LGND | Sale | 700 | 53.44 | 37,408 |
| 2013-12-06 | LGND | Sale | 6,000 | 56.08 | 336,480 |
| 2013-11-18 | LGND | Option Ex | 624 | 9.96 | 6,215 |
| 2013-11-18 | LGND | Sale | 1,123 | 53.00 | 59,519 |
| 2013-08-16 | LGND | Option Ex | 7,500 | 9.96 | 74,700 |
| 2013-08-16 | LGND | Sale | 7,500 | 42.75 | 320,617 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-11-03 | PHAS | Option Ex | 7,500 | 1.68 | 12,600 |
| 2020-08-14 | PHAS | Option Ex | 5,000 | 1.69 | 8,450 |
| 2019-08-21 | PHAS | Option Ex | 15,000 | 1.56 | 23,475 |
| 2019-05-22 | PHAS | Option Ex | 15,000 | 1.69 | 25,350 |
| 2018-12-07 | PHAS | Buy | 5,000 | 3.84 | 19,200 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Sharp John P (Chief Financial Officer of Phasebio Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.